• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

    2/19/25 6:00:00 AM ET
    $AEMD
    $ASPI
    $BDRX
    $BENF
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials
    Get the next $AEMD alert in real time by email

    MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    For updates, follow us on Twitter

    Day 2 - Today

    February 19, 2025

    Replay Day 1 here:

    https://emerginggrowth.com/emerging-growth-conference-79/

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 – 9:35

    Light.AI, Inc. (CBOE CA: ALGO) (FSE: 0HC)

    Keynote speaker: Hugh Cleland, Director

    9:40 – 10:10

    Biodexa Pharmaceuticals PLC (NASDAQ:BDRX)

    Keynote speaker: Stephen Anthony Stamp, CEO, CFO & Director

    10:15 – 10:45

    HydroGraph Clean Power Inc. (OTCQB:HGRAF) (CSE:HG)

    Keynote speaker: Kjirstin Breure, President and CEO

    10:50 – 11:20

    22nd Century Group, Inc. (NASDAQ:XXII)

    Keynote speaker: Lawrence D. Firestone, Chairman & CEO

    11:25 – 11:55

    Aethlon Medical, Inc. (NASDAQ:AEMD)

    Keynote speakers: Jim Frakes, Acting CEO and CFO & Steven LaRosa, Chief Medical Officer

    12:00 – 12:30

    Gossamer Bio, Inc. (NASDAQ:GOSS)

    Keynote speaker: Bryan Giraudo, CFO & COO

    12:35 – 1:05

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: Dr. David Platt, CEO & Mike Sheikh, Executive Vice President Business Development

    1:10 - 1:40

    ANGLE, plc. (OTCQX:ANPCY) (AIM: AGL)

    Keynote speakers: Andrew David William Newland, Founder, CEO & Executive Director

    1:45 - 2:15

    Touchstone Explorations, Inc. (OTC:PBEGF) (TSX:TXP) 

    Keynote speaker: Paul Raymond Baay President, CEO

    2:20 – 2:50

    Mesoblast, Ltd. (NASDAQ:MESO)

    Keynote speakers: Dr. Silviu Itescu, Founder, CEO

    2:55 – 3:05

    GeoVax Labs, Inc. (NASDAQ:GOVX)

    Keynote speakers: David Dodd, Chairman, President / CEO

    3:10 - 3:20

    Longeveron, Inc. (NASDAQ:LGVN)

    Keynote speaker: Mohamed Wa'el Hashad, CEO & Director

    3:25 - 3:35

    U Power Limited (NASDAQ:UCAR) 

    Keynote speaker: Paul Li, UCAR European Representative

    3:40 – 3:50

    Eloro Resources, Ltd. (OTCQX:ELRRF) (TSX:ELO)

    Keynote speakers: Thomas Larsen, CEO & Chairman, & Dr. William N. Pearson, Executive Vice President of Exploration

    3:55 – 4:05

    The Birch Co. (OTC:ATWT)

    Keynote speaker: Angus Martin, President & CEO

    4:10 – 4:40

    Sigyn Therapeutics, Inc. (OTCQB:SIGY)

    Keynote speaker: James Allen Joyce, CEO

    _______________________________________________________________

    Day 1

    February 18, 2025

    Companies presented yesterday:

    Replay Day 1 here:

    https://emerginggrowth.com/emerging-growth-conference-79/

    B.O.S. Better Online Solutions, Ltd. (NASDAQ:BOSC)

    Keynote speaker: Eyal Cohen, President & CEO

    Brenmiller Energy, Ltd. (NASDAQ:BNRG)

    Keynote speaker: Nir Brenmiller, COO

    Immuron Limited (NASDAQ:IMRN)

    Keynote speaker: Steve Lydeamore, CEO

    ASP Isotopes Inc. (NASDAQ:ASPI)

    Keynote speaker: Paul Elliot Mann, CEO

    U.S. Energy Corporation (NASDAQ:USEG)

    Keynote speaker: Ryan Smith, President, CEO & Director

    Empire Energy (ASX: EEG)

    Keynote speaker: Alex Underwood, CEO & Managing Director

    Nova Minerals Limited (NASDAQ:NVA) (ASX: NVA) 

    Keynote speaker: Christopher Gerteisen – CEO & Executive Director

    Highland Copper Company Inc. (OTCQB:HDRSF) (TSXV:HI)

    Keynote speaker: Barry O'Shea, CEO

    Collective Mining, Ltd. (NYSE:CNL) (TSX:CNL)

    Keynote speaker: Ari Sussman, Executive Chairman

    Ideal Power, Inc. (NASDAQ:IPWR)

    Keynote speakers: Dan Brdar, President / CEO, and Tim Burns CFO

    West Red Lake Gold Mines Ltd. (OTCQB:WRLGF) (TSXV:WRLG)

    Keynote Speaker: Gwen Preston, Vice President, Communications

    Beneficient (NASDAQ:BENF)

    Keynote speaker: Brad K. Heppner, CEO

    Jaguar Health, Inc. (NASDAQ:JAGX)

    Keynote speaker: Lisa A. Conte, Founder, CEO, President & Director

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, & Harry M. Lander, Ph.D. Senior Scientific Consultant

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients.  Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future.  In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $ASPI
    $BDRX
    $BENF

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    3/23/2026Overweight → Neutral
    Cantor Fitzgerald
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Gossamer Bio Inc.
    $GOSS
    1/28/2026$9.00Overweight
    Barclays
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    More analyst ratings

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Gossamer Bio from Overweight to Neutral

    3/23/26 8:26:50 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00

    2/24/26 8:01:18 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Barclays with a new price target

    Barclays downgraded Gossamer Bio from Overweight to Equal Weight and set a new price target of $0.30

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Shah Chetan

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    4/1/26 7:27:48 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Gikakis Nicolas

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    4/1/26 7:27:34 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Broenniman Edward G

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    4/1/26 7:27:18 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    SEC Filings

    View All

    SEC Form 6-K filed by Nova Minerals Limited

    6-K - Nova Minerals Ltd (0001852551) (Filer)

    4/1/26 4:22:33 PM ET
    $NVA
    Precious Metals
    Basic Materials

    SEC Form NT 10-K filed by Jaguar Health Inc.

    NT 10-K - Jaguar Health, Inc. (0001585608) (Filer)

    4/1/26 4:19:05 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by ASP Isotopes Inc.

    NT 10-K - ASP Isotopes Inc. (0001921865) (Filer)

    3/31/26 5:15:16 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $AEMD
    $ASPI
    $BDRX
    $BENF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

    4/1/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    Brenmiller Adds ISO/IEC 42001 Certification to Support AI-Enabled Optimization as Commercial TES Deployments and BNRG360 Strategy Scale

    Certification supports AI use across system optimization, predictive maintenance and forecasting as an additional milestone supporting Brenmiller's BNRG360 strategy and advances toward broader commercial scaleRosh Haayin, Israel--(Newsfile Corp. - March 31, 2026) - Brenmiller Energy Ltd. (NASDAQ:BNRG) ("Brenmiller," "Brenmiller Energy" or the "Company"), a provider of integrated power and heat solutions for industrial and utility customers built around its proprietary thermal energy storage ("TES") technology, today announced that it has achieved ISO/IEC 42001:2023 certification for its artificial intelligence ("AI") management system.The certification covers Brenmiller's use of AI across en

    3/31/26 8:05:00 AM ET
    $BNRG
    Building Products
    Industrials

    BOS Reports Financial Results for the Fourth Quarter and Full Year 2025

    Delivers Record Year Performance Provides Initial 2026 Revenue and Net Income Guidance RISHON LE ZION, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BOS Better Online Solutions Ltd. (BOSC) today reported financial results for the fourth quarter and full-year ended December 31, 2025, including record revenue and profitability. Fourth Quarter 2025 Financial Highlights: Revenues$12.6M +21.5%Compared to $10.4M in Q4 2024EBITDA$944K +32%Compared to $715K in Q4 2024Net Income$819K +68.9%Compared to $485K in Q4 2024EPS$0.12 +50%Compared to $0.08 in Q4 2024Cash & Equivalent$11.8MAs of December 31, 2025Contracted Backlog$24MAs of December 31, 2025 Full Year 2025 Financial Highlights: Reven

    3/31/26 7:30:00 AM ET
    $BOSC
    Computer Communications Equipment
    Telecommunications

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Somo David M bought $250,000 worth of shares (90,909 units at $2.75), increasing direct ownership by 37% to 338,347 units (SEC Form 4)

    4 - Ideal Power Inc. (0001507957) (Issuer)

    2/26/26 8:49:32 AM ET
    $IPWR
    Semiconductors
    Technology

    CEO Smith Ryan Lewis bought $4,560 worth of shares (4,000 units at $1.14), increasing direct ownership by 0.34% to 1,183,039 units (SEC Form 4)

    4 - US ENERGY CORP (0000101594) (Issuer)

    9/15/25 7:00:12 AM ET
    $USEG
    Oil & Gas Production
    Energy

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Financials

    Live finance-specific insights

    View All

    BOS Reports Financial Results for the Fourth Quarter and Full Year 2025

    Delivers Record Year Performance Provides Initial 2026 Revenue and Net Income Guidance RISHON LE ZION, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BOS Better Online Solutions Ltd. (BOSC) today reported financial results for the fourth quarter and full-year ended December 31, 2025, including record revenue and profitability. Fourth Quarter 2025 Financial Highlights: Revenues$12.6M +21.5%Compared to $10.4M in Q4 2024EBITDA$944K +32%Compared to $715K in Q4 2024Net Income$819K +68.9%Compared to $485K in Q4 2024EPS$0.12 +50%Compared to $0.08 in Q4 2024Cash & Equivalent$11.8MAs of December 31, 2025Contracted Backlog$24MAs of December 31, 2025 Full Year 2025 Financial Highlights: Reven

    3/31/26 7:30:00 AM ET
    $BOSC
    Computer Communications Equipment
    Telecommunications

    22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

    VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci

    3/26/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Leadership Updates

    Live Leadership Updates

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beneficient Appoints Mack H. Hicks to Board of Directors

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ:BENF), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced the appointment of Mack H. Hicks as a member of the Company's Board of Directors (the "Board"). Mr. Hicks currently serves as Chief Executive Officer of Hicks Holdings LLC, the Dallas-based family office with operating private equity and real estate investment businesses founded by his late father and private equity pioneer, Thomas O. Hicks, who served as Chairman of the Board of Beneficient until his passing in December of 2025. Mr. Hicks also

    3/12/26 7:30:00 AM ET
    $BENF
    Finance: Consumer Services
    Finance

    Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs i

    3/11/26 7:21:39 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Brenmiller Energy Ltd

    SC 13D/A - Brenmiller Energy Ltd. (0001901215) (Subject)

    12/5/24 11:18:20 AM ET
    $BNRG
    Building Products
    Industrials

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care